Ivonescimab

Name: Ivonescimab in EGFR-mutated non-small-cell lung cancer: Access and distribution
Published: 2026-09-14T15:39:06-04:00

EGFR-mutated non-small-cell lung cancer

Manufacturer: Summit Therapeutics
Regulatory submission: BLA submitted in the fourth quarter of 2025
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information

Access and distribution

1 evidence topic · 1 source

Expanded access

“in exceptional circumstances, Summit will consider a treating physician's request for single-patient expanded access to ivonescimab in the United States and Canada” (opens the source at this quote in a new tab)